PARD (Poniard Pharmaceuticals) Cash Flow from Financing: $-10.81 Mil (TTM As of Sep. 2011)

Poniard Pharmaceuticals  (OTCPK:PARD) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Poniard Pharmaceuticals's issuance of stock for the three months ended in Sep. 2011 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Poniard Pharmaceuticals's repurchase of stock for the three months ended in Sep. 2011 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Poniard Pharmaceuticals's net issuance of debt for the three months ended in Sep. 2011 was $0.00 Mil. Poniard Pharmaceuticals received $0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Poniard Pharmaceuticals's net issuance of preferred for the three months ended in Sep. 2011 was $0.00 Mil. Poniard Pharmaceuticals paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Poniard Pharmaceuticals's cash flow for dividends for the three months ended in Sep. 2011 was $0.00 Mil. Poniard Pharmaceuticals received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Poniard Pharmaceuticals's other financing for the three months ended in Sep. 2011 was $0.00 Mil. Poniard Pharmaceuticals received $0.00 Mil on other financial activities.

Poniard Pharmaceuticals Cash Flow from Financing Related Terms

The historical data trend for Poniard Pharmaceuticals's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poniard Pharmaceuticals Cash Flow from Financing Chart

Poniard Pharmaceuticals Annual Data
	Trend	Dec01	Dec02	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10
Cash Flow from Financing		Get a 7-Day Free Trial					72.74	65.38	14.01	6.13	-14.40

Poniard Pharmaceuticals Quarterly Data
	Dec06	Mar07	Jun07	Sep07	Dec07	Mar08	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11
Cash Flow from Financing	Get a 7-Day Free Trial															-1.97	-13.90	3.18	-0.10	0.00

Poniard Pharmaceuticals Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Poniard Pharmaceuticals's Cash from Financing for the fiscal year that ended in Dec. 2010 is calculated as:

Poniard Pharmaceuticals's Cash from Financing for the quarter that ended in Sep. 2011 is:

Cash Flow from Financing for the trailing twelve months (TTM) ended in Sep. 2011 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.81 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poniard Pharmaceuticals Business Description